Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Status:
Withdrawn
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This research trial studies the immune changes following trabectedin in patients with sarcoma
that has spread to other places in the body (metastatic) or cannot be removed by surgery
(unresectable). Analyzing tumor tissue may help to understand the changes in immune cells in
or around the tumor or if there is an increase in immune cells in the tumor after receiving
trabectedin.
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Janssen Pharmaceuticals National Cancer Institute (NCI)